Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin after PCI in patients with type 2 diabetes
IRCT20210612051550N1Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Empagliflozin + standard of care with Placebo + standard of care (2 arms). Primary endpoints: Incidence of major adverse cardiovascular events, Non-fatal myocardial infarction and 5 more. Started Jul 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20210612051550N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210612051550N1.